Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | GFER | P55789 | 1/20 | 0.49 |
| ▸ | GSK3B | P49841 | 2/20 | 0.49 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.47 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.47 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.47 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.47 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.47 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.47 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.47 |
| ▸ | F3 | P13726 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1769027 | 1.00 | CYP1A2 (0.57) | CYP1A2KMT2APOLBSMN1; SMN2NPC1 | |
| SCHEMBL23326817 | 1.00 | CYP1A2 (0.57) | CYP1A2KMT2APOLBSMN1; SMN2NPC1 | |
| SCHEMBL7630936 | 0.98 | CYP1A2 (0.55) | CYP1A2KMT2APOLBSMN1; SMN2NPC1 | |
| SCHEMBL1769120 | 0.85 | KMT2A (0.58) | CYP1A2KMT2APOLBSMN1; SMN2NPC1 | |
| SCHEMBL1769121 | 0.85 | KMT2A (0.58) | CYP1A2KMT2APOLBSMN1; SMN2NPC1 | |
| SCHEMBL23345343 | 0.85 | KMT2A (0.58) | CYP1A2KMT2APOLBSMN1; SMN2NPC1 | |
| SCHEMBL23345380 | 0.83 | KMT2A (0.53) | CYP1A2KMT2APOLBSMN1; SMN2RAB9A | |
| SCHEMBL7630927 | 0.83 | KMT2A (0.53) | CYP1A2KMT2APOLBSMN1; SMN2THRB | |
| SCHEMBL7630934 | 0.83 | KMT2A (0.53) | CYP1A2KMT2APOLBSMN1; SMN2THRB | |
| SCHEMBL6117540 | 0.82 | CYP1A2 (0.53) | CYP1A2KMT2APOLBSMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115108938-B | Chiral alpha-substituted deuterated amino acid compound and preparation method thereof | 武汉大学 | 2024-04-19 | — | — | CN | disclosed |
| US-9321769-B2 | Heterocyclic acrylamides and their use as pharmaceuticals | FAB PHARMA S.A.S. (FR) | 2016-04-26 | — | — | US | disclosed |
| US-20150232466-A1 | NOVEL HETEROCYCLIC ACRYLAMIDES AND THEIR USE AS PHARMACEUTICALS | FAB PHARMA S.A.S. (FR) | 2015-08-20 | — | — | US | disclosed |
| US-9051321-B2 | Heterocyclic acrylamides and their use as pharmaceuticals | FAB PHARMA S.A.S. (FR) | 2015-06-09 | — | — | US | disclosed |
| US-20140357617-A1 | NOVEL HETEROCYCLIC ACRYLAMIDES AND THEIR USE AS PHARMACEUTICALS | FAB PHARMA S.A.S. (FR) | 2014-12-04 | — | — | US | disclosed |
| US-8846711-B2 | Heterocyclic acrylamides and their use as pharmaceuticals | FAB PHARMA S.A.S. (FR) | 2014-09-30 | — | — | US | disclosed |
| EP-2501693-B1 | AZA HETEROCYCLIC ACRYLAMIDES AND THEIR USE AS BACTERICIDES | FAB PHARMA SAS (FR) | 2014-09-17 | — | — | EP | disclosed |
| US-20120277207-A1 | NOVEL HETEROCYCLIC ACRYLAMIDES AND THEIR USE AS PHARMACEUTICALS | FAB PHARMA S.A.S. (FR) | 2012-11-01 | — | — | US | disclosed |
| EP-2501693-A1 | NOVEL HETEROCYCLIC ACRYLAMIDES AND THEIR USE AS PHARMACEUTICALS | FAB Pharma SAS (FR) | 2012-09-26 | — | — | EP | disclosed |
| WO-2011061214-A1 | NOVEL HETEROCYCLIC ACRYLAMIDES AND THEIR USE AS PHARMACEUTICALS | FAB PHARMA SAS (FR) | 2011-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150232466-A1 | NOVEL HETEROCYCLIC ACRYLAMIDES AND THEIR USE AS PHARMACEUTICALS | ACR, AADAC, AAAS | CYP1A2 237/4885KMT2A 4479/4885POLB 2880/4885 |
| US-20140357617-A1 | NOVEL HETEROCYCLIC ACRYLAMIDES AND THEIR USE AS PHARMACEUTICALS | ACR, AADAC, AAAS | CYP1A2 237/4885KMT2A 4479/4885POLB 2880/4885 |
| US-20120277207-A1 | NOVEL HETEROCYCLIC ACRYLAMIDES AND THEIR USE AS PHARMACEUTICALS | ACR, AADAC, AAAS | CYP1A2 237/4885KMT2A 4479/4885POLB 2880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.